Mouse Model of Familial Hypertrophic Cardiomyopathy with E99K ACTC Mutation Recapitulates Many Features of Hypertrophic Cardiomyopathy in Patients

Mouse Model of Familial Hypertrophic Cardiomyopathy with E99K ACTC Mutation Recapitulates Many Features of Hypertrophic Cardiomyopathy in Patients

Detalles Bibliográficos
Autores principales:	Song, W, Dyer, E, Wells, D, Harding, SE, Stuckey, D, Carr, C, Clarke, K, Marston, S
Formato:	Conference item
Publicado:	2008

Ejemplares similares

PHENOTYPE OF THE ACTC E99K TRANSGENIC MOUSE REPRODUCES HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS
por: Song, W, et al.
Publicado: (2010)

Mouse HCM Model Expression E99K ACTC Mutation Reproduces the Clinical HCM Phenotype
por: Song, W, et al.
Publicado: (2009)

Age and strain related aberrant Ca(2+) release is associated with sudden cardiac death in the ACTC E99K mouse model of hypertrophic cardiomyopathy
por: Rowlands, C, et al.
Publicado: (2017)

Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.
por: Hudsmith, L, et al.
Publicado: (2006)

How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
por: Marston, S, et al.
Publicado: (2012)

Investigation of troponin I mutations causing familial hypertrophic cardiomyopathy
por: Abdulrazzak, H, et al.
Publicado: (2001)

Investigation of a mouse model of familial DCM with ACTC E361G mutation
por: Song, W, et al.
Publicado: (2008)

Sudden death in hypertrophic cardiomyopathy.
por: Watkins, H
Publicado: (2000)

Myocardial dysfunction in hypertrophic cardiomyopathy.
por: Ashrafian, H, et al.
Publicado: (2001)

The genetic architecture of hypertrophic cardiomyopathy
por: Harper, AR
Publicado: (2020)

Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin
por: Toepfer, C, et al.
Publicado: (2019)

Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy
por: Ashrafian, H, et al.
Publicado: (2005)

Linked genetic modifiers in hypertrophic cardiomyopathy
por: Ektisham, J, et al.
Publicado: (2004)

The genetics of hypertrophic cardiomyopathy: Teare redux.
por: Watkins, H, et al.
Publicado: (2008)

Correlates of myocardial fibrosis in hypertrophic cardiomyopathy
por: Kramer, CM, et al.
Publicado: (2018)

Comparison of the functional effects of mutations in troponin T which cause dilated and hypertrophic cardiomyopathies
por: Robinson, P, et al.
Publicado: (2002)

Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy.
por: Geier, C, et al.
Publicado: (2008)

Cardiac Steatosis Detected in Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy and Aortic Stenosis
por: Suttie, J, et al.
Publicado: (2011)

Metabolomics in hypertrophic cardiomyopathy and other myocardial diseases
por: Pal, N
Publicado: (2015)

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
por: Coleman, JA, et al.
Publicado: (2024)

Is DNA testing for hypertrophic cardiomyopathy cost-effective?
por: Wordsworth, S, et al.
Publicado: (2006)

Data-driven modelling of mutational hotspots and in silico predictors in hypertrophic cardiomyopathy
por: Waring, A, et al.
Publicado: (2020)

Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy.
por: Blair, E, et al.
Publicado: (2001)

Early onset malignant hypertrophic cardiomyopathy caused by mutations in MYBPC3
por: Carballo, S, et al.
Publicado: (2003)

Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy.
por: Geier, C, et al.
Publicado: (2003)

Molecular mechanism of the E99K mutation in cardiac actin (ACTC Gene) that causes apical hypertrophy in man and mouse.
por: Song, W, et al.
Publicado: (2011)

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry
por: Neubauer, S, et al.
Publicado: (2019)

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.
por: Ashrafian, H, et al.
Publicado: (2003)

Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies.
por: Watkins, H
Publicado: (2003)

Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.
por: Ashrafian, H, et al.
Publicado: (2011)

Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy.
por: Edwards, R, et al.
Publicado: (1970)

The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy.
por: Watkins, H, et al.
Publicado: (2005)

Ascertainment strategies and genotype:phenotype correlations in hypertrophic cardiomyopathy.
por: Blair, E, et al.
Publicado: (2003)

The arrhythmic substrate of hypertrophic cardiomyopathy using ECG imaging
por: Chow, J, et al.
Publicado: (2024)

EFFECTS OF PROPRANOLOL ON RESPONSE TO EXERCISE IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
por: Edwards, R, et al.
Publicado: (1970)

Pharmacological management of hypertrophic cardiomyopathy: From bench to bedside
por: Palandri, C, et al.
Publicado: (2022)

Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy
por: Coleman, JA, et al.
Publicado: (2023)

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry
por: Neubauer, S, et al.
Publicado: (2019)

Double mutations in CIS can confound genotype-phenotype correlations in hypertrophic cardiomyopathy
por: Blair, E, et al.
Publicado: (2000)

Novel mutations in cardiac MYBPC3 and early onset malignant hypertrophic cardiomyopathy
por: Carballo, S, et al.
Publicado: (2005)